Close Menu

Philadelphia Health and Education Corporation of Philadelphia has received US Patent No. 8,206,899, "Prostate cancer-related compositions, methods and kits based on DNA microarray proteomics platforms." Methods of detecting and treating prostate cancer are claimed that include modulating or detecting PCADM-1 gene expression and the production and activity of the PCADM-1 polypeptide. Arrays are also claimed for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.

The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.

Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.

In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.